{"title":"Delivering a new generation of translational animal models for depression research.","authors":"Emma S J Robinson","doi":"10.1097/FBP.0000000000000819","DOIUrl":null,"url":null,"abstract":"<p><p>Early animal models of depression focused on developing methods that could predict treatment efficacy and were validated based on pharmacological responses to known antidepressants. As our understanding of major depressive disorder (MDD) and the pharmacology of antidepressants progressed, so did the need for better animal models. This need was met with the development of new disease models, such as the chronic mild stress model, and behavioural readouts such as the sucrose preference test, which more closely aligned with risk factors and symptoms seen in patients. These approaches have supported huge advances in the understanding of how stress affects the brain and impacts on reward-related behaviours. However, there remain significant challenges when trying to model complex psychiatric symptoms and disorders in non-human animals. In this perspective article, a brief history of animal models of depression and associated readouts is discussed with specific reference to the important contributions from Paul Willner. The main discussion then focuses on translational validity and approaches that may support delivering this objective. This is illustrated with the example of the affective bias test and reward learning assays, which have been developed to recapitulate in animals the neuropsychological impairments observed in MDD and modulation by antidepressants.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":"36 4","pages":"175-181"},"PeriodicalIF":1.6000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Behavioural Pharmacology","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1097/FBP.0000000000000819","RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BEHAVIORAL SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Early animal models of depression focused on developing methods that could predict treatment efficacy and were validated based on pharmacological responses to known antidepressants. As our understanding of major depressive disorder (MDD) and the pharmacology of antidepressants progressed, so did the need for better animal models. This need was met with the development of new disease models, such as the chronic mild stress model, and behavioural readouts such as the sucrose preference test, which more closely aligned with risk factors and symptoms seen in patients. These approaches have supported huge advances in the understanding of how stress affects the brain and impacts on reward-related behaviours. However, there remain significant challenges when trying to model complex psychiatric symptoms and disorders in non-human animals. In this perspective article, a brief history of animal models of depression and associated readouts is discussed with specific reference to the important contributions from Paul Willner. The main discussion then focuses on translational validity and approaches that may support delivering this objective. This is illustrated with the example of the affective bias test and reward learning assays, which have been developed to recapitulate in animals the neuropsychological impairments observed in MDD and modulation by antidepressants.
期刊介绍:
Behavioural Pharmacology accepts original full and short research reports in diverse areas ranging from ethopharmacology to the pharmacology of schedule-controlled operant behaviour, provided that their primary focus is behavioural. Suitable topics include drug, chemical and hormonal effects on behaviour, the neurochemical mechanisms under-lying behaviour, and behavioural methods for the study of drug action. Both animal and human studies are welcome; however, studies reporting neurochemical data should have a predominantly behavioural focus, and human studies should not consist exclusively of clinical trials or case reports. Preference is given to studies that demonstrate and develop the potential of behavioural methods, and to papers reporting findings of direct relevance to clinical problems. Papers making a significant theoretical contribution are particularly welcome and, where possible and merited, space is made available for authors to explore fully the theoretical implications of their findings. Reviews of an area of the literature or at an appropriate stage in the development of an author’s own work are welcome. Commentaries in areas of current interest are also considered for publication, as are Reviews and Commentaries in areas outside behavioural pharmacology, but of importance and interest to behavioural pharmacologists. Behavioural Pharmacology publishes frequent Special Issues on current hot topics. The editors welcome correspondence about whether a paper in preparation might be suitable for inclusion in a Special Issue.